Flubrotizolam
[CAS# 57801-95-3]

Identification

• Name: Flubrotizolam
• Synonyms: 2-Bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine
• Molecular Formula: C₁₅H₁₀BrFN₄S
• Molecular Weight: 377.23
• CAS Registry Number: 57801-95-3
• SMILES: CC1=NN=C2N1C3=C(C=C(S3)Br)C(=NC2)C4=CC=CC=C4F

Properties

• Solubility: 0.01574 mg/L (25 °C water)
• Density: 1.8±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.778, Calc.^*
• Melting point: 182.28 °C
• Boiling Point: 435.09 °C, 535.7±60.0 °C (760 mmHg), Calc.^*
• Flash Point: 277.8±32.9 °C, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Discovery and Applications

Flubrotizolam, a chemical compound belonging to the benzodiazepine class, was first synthesized and discovered in the laboratory during research into novel psychoactive substances. It was developed as an analog of benzodiazepines with potent sedative, anxiolytic, and hypnotic properties. The discovery of Flubrotizolam occurred in recent years, with its chemical structure confirmed through spectroscopic analysis and pharmacological testing.

Flubrotizolam has potential applications in the medical field for its sedative and anxiolytic properties. It may be prescribed for the short-term management of severe anxiety disorders and insomnia under medical supervision.

Flubrotizolam is utilized in scientific research to study its pharmacological effects, mechanisms of action, and potential therapeutic uses. Researchers investigate its efficacy and safety profile compared to other benzodiazepines.

In forensic toxicology, Flubrotizolam is analyzed in biological samples to detect its presence in cases involving drug-related incidents, including overdose or impaired driving.

Due to its potent sedative effects, Flubrotizolam may be misused recreationally for its euphoric and calming effects. However, its use outside medical supervision poses significant risks of dependence, overdose, and adverse reactions.

Flubrotizolam may find applications in veterinary medicine for its sedative and anxiolytic effects in animals, although further research is needed to establish its safety and efficacy in veterinary practice.

References

2022. In silico studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and de novo designer benzodiazepines. Chemical Biology & Drug Design, 100(4).
DOI: 10.1111/cbdd.14119